Compare Mesoblast Limited (MESO) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nokia Corp — how do they compare? Mesoblast Limited trades at $16.86 (market cap $2.21B), while Nokia Corp trades at $10.35 (market cap $53.00B). The key difference: Nokia Corp is far larger — about 24× Mesoblast Limited's market cap, and Nokia Corp pays a 1.73% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NOK | |
|---|---|---|
Market Cap | $2.21B | $53.00B |
Sector | Technology | Technology |
52-Week High | $20.96 | $16.83 |
52-Week Low | $12.88 | $4.13 |
Enterprise Value | $2.21B | $50.95B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Nokia (NOK) trades at $10.375, up 13.76% today, reflecting strong momentum amid AI infrastructure demand. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, Q2 2026 earnings beat profit estimates, driven by AI and cloud growth, though revenue missed. Analyst sentiment is bullish with 60% buy ratings, while cash flow trends indicate volatility with a net outflow of $1.16B in 2025.
The outlook is cautiously optimistic, with AI-driven demand offsetting telecom challenges. Key opportunities include expanding AI networking and cloud infrastructure, but risks involve uneven telecom spending and competitive pressures. Investors should weigh strong analyst support against cash flow instability and margin pressures for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
